Biotech & Pharma

New biotech Slate Medicines raises $130M for migraine drug from China

28 sec read60 views0 listens

Slate Medicines, a Chinese biotech startup, secured $130 million in Series A funding to develop a new class of migraine drugs, joining global efforts in this therapeutic area. This investment underscores growing international interest and competition in addressing unmet needs for effective migraine treatments. For content creators, the focus on innovative drug development highlights opportunities in reporting on emerging biotech trends and startup successes from China.

Read the full article at Endpoints News

Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.

You Might Like

Legal & Policy1 day ago32 sec read

A Tribute, A Tactic, Or An Appellate Issue?

A prosecutor's use of hair bows in the Lindsay Clancy murder trial is being scrutinized as a potential tactic that could lead to an appeal, rather than relying solely on evidence. Separately, private equity firm Charlesbank Capital Partners is report...

Ali Nemati

Biotech & PharmaJul 2226 sec read

Transcripta Bio Raises $24M for AI-Driven Neurological Disease Therapies

Transcripta Bio, an AI-driven drug discovery startup, has raised $24 million to advance its neurological disease therapies. The funding will support clinical preparations for conditions like autism spectrum disorder and muscular dystrophy, leveraging...

Ali Nemati

Biotech & PharmaJun 1428 sec read

StockWatch: Parabilis Medicines Makes Wall Street History with $770.5M IPO

Parabilis Medicines achieved a record-breaking $770.5 million IPO, the largest ever for a drug developer, with its stock experiencing a significant initial jump. This event is highly relevant for developers and professionals in the biotech and pharma...

Ali Nemati